Business Wire

Zambia sets global benchmark for community forest conservation

10.9.2020 11:29:00 EEST | Business Wire | Press release

Share

Twelve communities in the Luangwa Valley are benefitting from direct cash payments of K50 million ($2.3 million) thanks to a partnership with forest conservation business BCP (BioCarbon Partners).

The ground-breaking Lower Zambezi REDD+ Project (LZRP) and Luangwa Community Forests Project (LCFP), facilitated by BCP in partnership with communities, the Zambian Forestry Department and Department of National Parks and Wildlife have resulted in direct monetisation of forest resources by local people.

The public-private-community projects set a new standard in forest conservation that puts the nation at the forefront of global efforts to combat climate change, while protecting forest resources and creating livelihood opportunities for local people.

His Royal Highness Chief Bunda Bunda said: “My community has worked hard towards this REDD+ verification success for Zambia. We thank the government for helping our Chiefdom to access REDD+ benefits and to BCP for the partnership, which has increased employment, livelihoods and development projects.”

LZRP is the world’s first REDD+ project to pass seven Verified Carbon Standard (VCS) audits, enabling income to be generated from credits that offset the carbon footprints of organisations producing greenhouse gases. LZRP was also the first REDD+ project in Africa to achieve triple-gold validation under the Climate, Community and Biodiversity Standard for exceptional social impact.

BCP CEO Dr Hassan Sachedina said: “We are privileged to support government and community efforts to conserve the Luangwa-Lower Zambezi ecosystem, one of the greatest remaining wildlife strongholds on earth.

“This has been a tough year due to the pandemic; tourism and conservation funding have declined, but through the extraordinary efforts of our partners such as Forestry Department, the LCFP has channelled K50 million into communities in 2020. We are grateful for USAID backing the LCFP’s development. This is just the beginning of a long-term, self-sustainable conservation model which benefits communities and wildlife”.

At 944,000 hectares, the triple-gold CCB validated LCFP is Africa’s largest project by hectares and improves the lives of 217,000 people in 12 chiefdoms, while LZRP covers 40,000 hectares and benefits 7,000 people in 1 chiefdom.

Ends

About BCP
BCP is a leading African conservation social enterprise with a mission to make wildlife habitat conservation valuable to people. BCP employs over 160 people across 13 chiefdoms in Zambia, partnering to help conserve 1 million hectares of habitat in critical ecosystems.
www.biocarbonpartners.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gina Woolley
+260 763 299 406

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye